CDC Acting Director Delays Publication of Study Showing COVID-19 Vaccine Effectiveness
Key Insights
Acting CDC (search) Director Dr. Jay Bhattacharya has delayed publication of a study scheduled for March 2026 release that demonstrated COVID-19 vaccines (search) reduced emergency department visits by 50% and hospitalizations by 55% among healthy adults.
The delayed study used a test-negative design methodology that has been routinely employed for two decades to measure flu and COVID vaccine effectiveness, with identical approaches recently published in peer-reviewed journals.
Public health experts express concern that the delay represents unprecedented political interference in CDC (search)'s scientific process, particularly given the well-established nature of the methodology being questioned.
Acting CDC (search) Director Dr. Jay Bhattacharya has delayed publication of a study demonstrating significant COVID-19 (search) vaccine effectiveness, citing concerns about methodology that has been standard practice for respiratory virus research for two decades. The study, originally scheduled for March 2026 release in the CDC's Morbidity and Mortality Weekly Report (MMWR), found that vaccinated healthy adults experienced a 50% reduction in emergency department and urgent care visits and a 55% decrease in COVID-associated hospitalizations compared to unvaccinated individuals during the September-December 2025 period.
Methodology Under Scrutiny
The delayed study employed a test-negative design, which CDC (search) spokesperson Andrew Nixon described as an "observational method" that Bhattacharya questioned. This methodology examines individuals sick enough to seek medical care and undergo testing, comparing vaccination rates between those who test positive versus negative for the virus.
Despite Bhattacharya's concerns, this approach has been the gold standard for measuring vaccine effectiveness against respiratory viruses for years. The New England Journal of Medicine published a 2021 study using identical methodology, and a flu vaccine study employing the same approach appeared in the MMWR just one week before the COVID vaccine study's scheduled publication.
Expert Concerns Over Scientific Independence
Dr. Fiona Havers, a former CDC (search) medical epidemiologist who resigned in protest after HHS Secretary Robert F. Kennedy Jr. restructured the agency's vaccine advisory committee, characterized the delay as unprecedented political interference. "To wholesale stop this report from coming out, given that it is such a well-established platform and such a well-established methodology, does strike me as a new level of political interference into CDC's scientific process," Havers stated.
Dan Jernigan, former head of CDC (search)'s influenza division and one of three senior leaders who resigned last summer, told the Washington Post that the blocked report's findings directly conflict with the administration's public direction on vaccines, making its suppression difficult to interpret as routine scientific review.
Broader Policy Context
The study delay occurs within a larger pattern of vaccine policy changes under the current administration. Kennedy, founder of a prominent anti-vaccine advocacy group, has publicly called COVID shots the "deadliest vaccine ever made" and recently fired the CDC (search)'s vaccine advisory committee, appointing new leadership.
Former FDA regulator Vinay Prasad has called for new restrictions on approved COVID-19 vaccines (search) from Novavax and Moderna, citing deaths of 10 children allegedly linked to COVID-19 (search) vaccination. A federal judge in March identified these vaccine policy changes as likely violations of the Administrative Procedure Act, finding the government bypassed required procedural safeguards.
Agency Response
CDC (search) spokesperson Andrew Nixon defended the delay, stating that "Dr. Bhattacharya wants to make sure that the paper uses the most appropriate methodology for such a study" and that "taking time to ensure analyses are methodologically sound and clearly communicated is always preferable to risking error."
Nixon emphasized that it is "routine for CDC (search) leadership to review and flag concerns about MMWR papers, especially relating to their methodology, leading up to planned publication."